Filing Flows › ARS Pharmaceuticals (SPRY) › Q2 2026
ARS Pharmaceuticals (SPRY) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
ARS Pharmaceuticals (SPRY) reported revenue of $33.7M for the second quarter 2026 (Q2 2026), +114% from a year earlier and +48% from the quarter before. Operating margin was -182.6%, net loss $62.3M (185.2% of revenue).
ARS Pharmaceuticals, Q2 2026: revenue $33.7M (+114% year over year), operating margin -182.6%, net loss $62.3M, operating cash flow −$60.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.7M | +48% | +114% |
| Operating profit | −$61.5M | — | — |
| Net earnings | −$62.3M | — | — |
| Operating cash flow | −$60.9M | — | — |
What changed
Revenue was $33.7M in Q2 2026, up 114% year over year and up 48% from the previous quarter. Product was the largest line at 78% of revenue. Product added $13.4M year over year (up 105%), 75% of the total change. Revenue Under Collaboration Agreements declined 98%.
Operating costs exceeded revenue by $61.5M, an operating margin of -182.6%. Total costs grew 50% against revenue growth of 114%. The fastest-growing cost line was Other operating costs (+158%). The quarter ended with a net loss of $62.3M, wider than the previous quarter's $60.6M loss.
Operating cash flow was −$60.9M. Non-cash charges added back $416K of depreciation and amortization and $12.4M of share-based compensation. Working capital and other items used $11.4M.
Questions
What was ARS Pharmaceuticals' revenue in the second quarter 2026?
ARS Pharmaceuticals (SPRY) reported revenue of $33.7M for the second quarter 2026 (Q2 2026), +114% from a year earlier and +48% from the quarter before.
Was ARS Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $61.5M (-182.6% of revenue) and net loss $62.3M.